



The 1st World Congress on Controversies in Lymphoma (COLYM)
October 14-15, 2022 – Virtual Event

Faculty disclosures report - *As of October 1, 2022*

The COLYM 2022 Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COLYM 2022 participants. In doing so, the COLYM 2022 Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The COLYM 2022 Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The COLYM 2022 Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the COLYM 2022 Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the COLYM 2022 Congress of CME based on the CME providers of the Congress.

All COLYM 2022 Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The COLYM 2022 Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

COLYM 2022 Financial Disclosure Codes

Type of affiliation / financial interest	Code
Receipt of grants/research supports:	S
Receipt of consultation / advisory board / employment fees:	C
Lecture and/or honoraria fees:	L
Stock shareholder or equity owner:	O
Patents/royalties:	P
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:



The 1st World Congress on Controversies in Lymphoma (COLYM)
October 14-15, 2022 – Virtual Event

Sairah Ahmed

Other Research funding from Seattle Genetics, Merck, Xencor, Tessa Therapeutics, membership on Tessa Therapeutic's advisory committee

Mary Ann Anderson

C,L AbbVie, Novartis, Gilead, Takeda, Janssen, Astra Zeneca

Farrukh Awan

C Genentech, Astra Zeneca, AbbVie, Janssen, Pharmacyclics, Gilead Sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Collector Biosciences

Paul Bröckelmann

S Beigene, BMS, MSD, Takeda
C Takeda

Carmello Carlo-Stella

S ADC Therapeutics, Roche, Sanofi
C Celgene/BMS< ADC Therapeutics, Karyopharm Therapeutics, Roche, Sanofi, Scenic Biotech
L BMS, Merck Sharp & Dohme, Janssen Oncology, Astra Zeneca, Incyte, Novartis, Takeda, ADC Therapeutics

Carlo Casulo

S Gilead, BMS, Genentech, Secura Bio (Verastem)

Kate Cwynarski

C Roche, Takeda, Celgene, Atara, Gilead, KITE, Janssen, Incyte
L Roche, Takeda, KITE, Gilead, Incyte

Daphne de Jong

Nothing to declare

Michael Dickinson

S Roche, Novartis, Takeda, Glead
C Roche, Novartis, BMS, Gilead, Kite, AbbVie
L Roche, Novartis, BMS, Gilead, Kite, AbbVie, Janssen

Kieron Dunleavy

C AbbVie, Astra Zeneca, Beigene, ADC Therapeutics, Morphosys, Genmab, Genentech

Narendranath Epperla

Nothing to declare

Timothy Fenske

Nothing to declare



The 1st World Congress on Controversies in Lymphoma (COLYM)
October 14-15, 2022 – Virtual Event

Christopher Fox

S Beigene
C AbbVie, Astra Zeneca, Atarabio, Celgene/BMS, GenMab, Gilead/Kite, Incyte, Morphosys, Lilly, Ono, Roche, Takeda
L Roche, Janssen, Incyte, Takeda

Andrea Gallamini

Nothing to declare

Nilanjan Ghosh

S TG Therapeutics, Genentech/Roche, BMS, Gilead, Morphosys, AbbVie
C Seagen, TG Therapeutics, Astra Zeneca, Pharmacyclics, Janssen, BMS, Gilead Sciences, Beigene, Incyte, Karyopharm, Roche Genentech, Novartis, Loxo Oncology, Genmab, Adaptive Biotech, ADC Therapeutics

Maria Gomes da Silva

C Gilead Sciences, Astra Zeneca
S Janssen, Gilead Sciences, MSD, Celgene, Roche, Takeda, Novartis, ADC Therapeutics
L Janssen

Eliza Hawkes

C Roche, BMS, Merck KgA, Astra Zeneca, Celgene
L Astra Zeneca, Roche, Regeneron

Caron Jacobson

S Kite/Gilead, Pfizer
C Kite/Gilead, Novartis, BMS/Celgene, bluebird bio, Epizyme, Instill Bio, Abintus Bio, Daiichi Sankyo, ImmPACT Bio, Caribou Bio

Mats Jerkeman

S Janssen, Gilead, Astra Zeneca, AbbVie, BMS, Roche
C Janssen, Gilead, Astra Zeneca, AbbVie, BMS, Roche, Genmab, Incyte, Orion, BioInvent

Manali Kamdar

S TG Therapeutics, Genentech, Novartis
C AbbVie, Astra Zeneca, Celgene/BMS, Adaptive Bio, ADC Therapeutics, BeiGene, Genentech, Impact bio
L SeaGen

Marie José Kersten

Nothing to declare

Mohamed Kharfan-Dabaja

Nothing to declare

Sean Lim

Nothing to declare



The 1st World Congress on Controversies in Lymphoma (COLYM)
October 14-15, 2022 – Virtual Event

Carmen Martinez

S Takeda, BMS, Novartis,
C Takeda, BMS

Roya Merie

Nothing to declare

Alberto Mussetti

S Gilead
C Merck, Takeda, Gilead, Merck, BMS

Lakshmi Nayak

Nothing to declare

Wendy Osborne

C Roche, Servier, Takeda, Kite Gilead, MSD, Novartis, Beigene, Syneos, Autolus, Kyowa Kirin, Incyte, BMS/Celgene
L Roche, Takeda, Pfizer, Kite Gilead, Novartis, Astra Zeneca, Kyowa Kirin, AbbVie, Incyte

Lia Palomba

Nothing to declare

Elizabeth Phillips

Nothing to declare

Mark Roschewski

Nothing to declare

Michael Scordo

Nothing to declare

Laurie Sehn

Nothing to declare

Mayzar Shadman

S Mustang Bio, Celgene, BMS< Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, Beigene, Astra Zeneca, Sunesis, Atara Biotherapeutics, Genmab, Morphosys/Incyte
C AbbVie, Genentech, Astra Zeneca, Sound Biologics, Pharmacyclics, Beigene, BMS, Morphosys/Incyte, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, Merck, Fate therapeutics, MEI pharma, Atara Biotherapeutics

Tanya Sidiqqi

S BMS
C Astra Zeneca, BMS, Beigene, Gilead, Celgene, Dava Oncology, AbbVie
L Astra Zeneca, BMS, Beigene

Matthew Wilson

Nothing to declare